APA (7th ed.) Citation

Klünder, B., Mittapalli, R. K., Mohamed, M. F., Friedel, A., Noertersheuser, P., & Othman, A. A. (2019). Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I–III Clinical Trials. Clinical pharmacokinetics, 58(8), 1045-1058. https://doi.org/10.1007/s40262-019-00739-3

Chicago Style (17th ed.) Citation

Klünder, Ben, Rajendar K. Mittapalli, Mohamed-Eslam F. Mohamed, Anna Friedel, Peter Noertersheuser, and Ahmed A. Othman. "Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I–III Clinical Trials." Clinical Pharmacokinetics 58, no. 8 (2019): 1045-1058. https://doi.org/10.1007/s40262-019-00739-3.

MLA (9th ed.) Citation

Klünder, Ben, et al. "Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I–III Clinical Trials." Clinical Pharmacokinetics, vol. 58, no. 8, 2019, pp. 1045-1058, https://doi.org/10.1007/s40262-019-00739-3.